0
Skip to Content
Maxwell Biosciences
HealthSpan
Pipeline
Technology
News
Team
Careers
Investors
Maxwell Biosciences
HealthSpan
Pipeline
Technology
News
Team
Careers
Investors
HealthSpan
Pipeline
Technology
News
Team
Careers
Investors
Joshua McClure 5/18/20 Joshua McClure 5/18/20

Maxwell Peptoids Active Against Herpes Simplex 1 (HSV-1)

Read More
Joshua McClure 6/11/19 Joshua McClure 6/11/19

Next Generation Virucides – Peptoids

Read More

Maxwell Biosciences, Inc.

Austin, Texas
United States of America

Company

HealthSpan
Pipeline
Technology
Team
Science
News
Careers
Investors

News

Featured
Maxwell Biosciences Selected to Receive a Nearly $3M Award from Medical Technology Enterprise Consortium (MTEC)
Maxwell Biosciences Enters Second CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral and Bacterial Pathogens
Maxwell Biosciences CEO J. Scotch McClure Named Top 25 Executive in Biotechnology
Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study
Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens

Science

Featured
Maxwell Peptoids Active Against Herpes Simplex 1 (HSV-1)
Next Generation Virucides – Peptoids

Copyright © 2016 - 2024. Maxwell Biosciences and CLAROMER are registered trademarks of Maxwell Biosciences, Inc. All rights reserved.

Unless otherwise stated, the information on this website has not been evaluated by the Food & Drug Administration. As a research organization, we do not diagnose, treat, cure or prevent any illness or disease. Information is shared for educational purposes only. You must consult your doctor before acting on any content on this website, especially if you are pregnant, nursing, taking medication, or have a medical condition.